Involuntary attention impairment in early Parkinson's disease: An event-related potential study

Solís-Vivanco, Rodolfo; Ricardo-Garcell, Josefina; Rodríguez-Camacho, Mario; Prado-Alcalá, Roberto A.; Rodríguez, Ulises Lima; Rodríguez-Violante, Mayela; Rodríguez-Agudelo, Yaneth

doi:10.1016/j.neulet.2011.03.058

Cited by 34 publications

(41 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although MMN amplitude in response to deviant sounds has been reported to be attenuated in non-demented PD patients in one study (Pekkonen et al, 1995), no such differences could be found in six other studies (Brønnick et al, 2010;Karayanidis et al, 1995;Pekkonen et al, 2000;Solís-Vivanco et al, 2011Vieregge et al, 1994). However, in the study by Brønnick et al (2010), MMN amplitude was markedly attenuated in PDD patients and, surprisingly, the extent of the MMN attenuation was more pronounced in PDD patients than it was in AD or DLB patients.…”

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 88%

“…P3a amplitude has been found to be attenuated in PD in some studies (Li et al, 2005;Solís-Vivanco et al, 2011Tsuchiya et al, 2000;Wang et al, 1999Wang et al, , 2000, but not in others (Bocquillon et al, 2012;Gaudreault et al, 2013;Georgiev et al, 2015;Hozumi et al, 2000;Pirtošek et al, 2001;Tachibana et al, 1992;Toda et al, 1993;Zeng et al, 2002 et al, 2000). In addition, smaller P3a amplitudes obtained from threestimulus oddball tasks have been associated with more efficient performance in more demanding tasks (Lange et al, 2015).…”

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 96%

“…When the P3a is recorded in the distraction paradigm (Schröger and Wolff, 1998), as for example in the studies by Solís-Vivanco et al (2011, it is typically preceded by the Mismatch Negativity (MMN), an index of relatively automatic deviance detection (Näätänen et al, 2007). In the distraction paradigm, participants are instructed to attend to one stimulus dimension (e.g., tone duration), while the presented stimuli also vary on a second, task-irrelevant dimension (e.g., tone pitch).…”

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 99%

See 2 more Smart Citations

Event-related potentials and cognition in Parkinson’s disease: An integrative review

Seer

Lange

Georgiev

et al. 2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 88%

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 96%

Section: P3b In Pd: Conclusion and Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Event-related potentials and cognition in Parkinson’s disease: An integrative review

Seer

Lange

Georgiev

et al. 2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

“…In addition to these, attentional difficulties are also very common in PD. Selective attention deficits (Zhou et al, 2012), problems with involuntary attention (Solis-Vivanco et al, 2011), attention set-shifting and flexibility deficits and disturbance of auditory attention (Bronnick, Nordby, Larsen, & Aarsland, 2010) have all been reported in PD patients. Therefore, a range of cognitive deficits, including attentional deficits, are common in early stage PD and have been directly related to the basic neuropathological changes in PD -decreased production of dopamine in SNpc, that leads to decreased concentration of dopamine in the striatum and consequently disturbed neuronal activity, primarily in the frontostriatal circuits including the associative circuit between the caudate and the dorsolateral prefrontal cortex (DLPFC) (Cools, 2006;Gotham, Brown, & Marsden, 1988).…”

Section: Introductionmentioning

confidence: 99%

“…Namely, dopaminergic medication may either alleviate or deteriorate cognitive function, or have no effect on cognitive function (Briand, Hening, Poizner, & Sereno, 2001;Bronnick et al, 2010;Cools, 2006Cools, , 2011Cools, Barker, Sahakian, & Robbins, 2001;Gauntlett-Gilbert, Roberts, & Brown, 1999;Gotham et al, 1988;Kiesel, Miller, Jolicoeur, & Brisson, 2008;Sawada et al, 2012;Solis-Vivanco et al, 2011;Tachibana, Toda, & Sugita, 1992;Tinaz, Courtney, & Stern, 2011;Tombaugh, 2004;Tsuchiya, Yamaguchi, & Kobayashi, 2000). It has been postulated that these contrasting effects of dopaminergic medication stem from an imbalance of dopamine in distinct regions of the striatum (Gotham et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

Dopaminergic medication alters auditory distractor processing in Parkinson's disease

et al. 2015

View full text Add to dashboard Cite

Auditory Dysfunction in Parkinson's Disease

2020

View full text Add to dashboard Cite

A BS TRACT: PD is a progressive and complex neurological disorder with heterogeneous symptomatology. PD is characterized by classical motor features of parkinsonism and nonmotor symptoms and involves extensive regions of the nervous system, various neurotransmitters, and protein aggregates. Extensive evidence supports auditory dysfunction as an additional nonmotor feature of PD. Studies indicate a broad range of auditory impairments in PD, from the peripheral hearing system to the auditory brainstem and cortical areas. For instance, research demonstrates a higher occurrence of hearing loss in early-onset PD and evidence of abnormal auditory evoked potentials, event-related potentials, and habituation to novel stimuli. Electrophysiological data, such as auditory P3a, also is suggested as a sensitive measure of illness duration and severity. Improvement in auditory responses following dopaminergic therapies also indicates the presence of similar neurotransmitters (i.e., glutamate and dopamine) in the auditory system and basal ganglia. Nonetheless, hearing impairments in PD have received little attention in clinical practice so far. This review summarizes evidence of peripheral and central auditory impairments in PD and provides conclusions and directions for future empirical and clinical research.Among neurological disorders, which are the leading cause of disability in the world, Parkinson's disease (PD) shows the highest growth in prevalence, rate of deaths, and disability-adjusted life-years between 1990 and 2015, and it is estimated to double over the next 20 years. 1 The etiology of PD is often unknown and mostly occurs in sporadic form, possibly arising from the association of genetic and environmental risk factors. 2,3 As a progressive disease, PD is characterized by early major death of dopaminergic neurons in the SNpc within the basal ganglia that leads to classical parkinsonian and secondary motor symptoms. 2,4 PD pathology involves extensive regions of the nervous system, various neurotransmitters (e.g., dopaminergic and nondopaminergic neurotransmitters), and protein aggregations other than just Lewy bodies or Lewy neurites (i.e., abnormal aggregation of insoluble α-synuclein protein [SNCA]) 2 that account for a wide range of clinical symptoms and signs observed in PD. 5 Thus, multiple nonmotor symptoms (NMSs) develop throughout the PD progress, some of which precede the motor dysfunction by more than a decade. 2 For instance, fatigue, neuropsychiatric symptoms, autonomic dysfunction, gastrointestinal symptoms, sensory deficits (e.g., visual impairments, 6 olfactory dysfunction, 7 taste disorders, 8 somatosensory abnormalities, 9 and auditory disorders 10,11 ), and sleep problems are within common NMSs in early PD. 2,3 Among sensory dysfunctions as NMSs of PD, somatic sensations, such as pain and paraesthesias, have received ---

show abstract

Involuntary attention impairment in early Parkinson's disease: An event-related potential study

Cited by 34 publications

References 30 publications

Event-related potentials and cognition in Parkinson’s disease: An integrative review

Event-related potentials and cognition in Parkinson’s disease: An integrative review

Dopaminergic medication alters auditory distractor processing in Parkinson's disease

Auditory Dysfunction in Parkinson's Disease

Contact Info

Product

Resources

About